Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
Trial details
- Registry ID
- NCT06435845
- Drugs studied
- Anti-(integrin beta-3) human monoclonal antibody
TrialRedline tracks 1 clinical trial sponsored by Rallybio: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a AlloimmunizationNCT06435845 | Anti-(integrin beta-3) human monoclonal antibody | Terminated | 2025-10-01Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of Participants with treatment related adverse events as defined by CTCAE 5.0 Measure: Maternal exposure to RLYB212 as measured in serum. After: Measure: Number of Participants With Treatment Related Adverse Events as Defined by CTCAE 5.0 Measure: Maternal Exposure to RLYB212 as Measured in Serum.
Before: Completed. After: Terminated.
Before: Estimated. After: Actual.
Before: 8 participants (planned). After: 1 participants (actual).
Before: Active not recruiting. After: Completed.